Recursion Pharmaceuticals (NASDAQ:RXRX) Director Namandje Bumpus Sells 3,963 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Namandje Bumpus sold 3,963 shares of the firm’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $3.18, for a total value of $12,602.34. Following the transaction, the director directly owned 127,632 shares in the company, valued at $405,869.76. This trade represents a 3.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Namandje Bumpus also recently made the following trade(s):

• On Wednesday, June 3rd, Namandje Bumpus sold 4,386 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.54, for a total value of $15,526.44.

Recursion Pharmaceuticals Trading Down 1.5%

Shares of RXRX stock opened at $3.18 on Tuesday. The business has a 50-day moving average of $3.32 and a 200 day moving average of $3.73. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.47 and a quick ratio of 5.47. Recursion Pharmaceuticals, Inc. has a 1-year low of $2.77 and a 1-year high of $7.18. The stock has a market capitalization of $1.69 billion, a PE ratio of -2.65 and a beta of 1.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The business had revenue of $6.47 million for the quarter, compared to analysts’ expectations of $15.78 million. During the same period in the previous year, the firm earned ($0.50) EPS. The business’s quarterly revenue was down 56.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.99 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Morgan Stanley lifted their target price on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research note on Thursday, May 14th. Needham & Company LLC reissued a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Bank of America cut their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. Finally, Wall Street Zen downgraded shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $8.10.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in RXRX. International Assets Investment Management LLC bought a new stake in Recursion Pharmaceuticals in the fourth quarter valued at $31,000. Integral Investment Advisors Inc. bought a new position in Recursion Pharmaceuticals in the 1st quarter worth $39,000. Sequoia Financial Advisors LLC bought a new position in Recursion Pharmaceuticals in the 4th quarter worth $41,000. MQS Management LLC purchased a new stake in shares of Recursion Pharmaceuticals in the 1st quarter worth about $41,000. Finally, Allworth Financial LP lifted its position in shares of Recursion Pharmaceuticals by 85.6% in the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock worth $47,000 after purchasing an additional 4,403 shares during the period. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.